{"nctId":"NCT01212471","briefTitle":"A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease","startDateStruct":{"date":"2010-09"},"conditions":["Dry Eye Syndrome"],"count":840,"armGroups":[{"label":"Bromfenac Ophthalmic Solution A","type":"EXPERIMENTAL","interventionNames":["Drug: Bromfenac Ophthalmic Solution A"]},{"label":"Bromfenac Ophthalmic Solution B","type":"EXPERIMENTAL","interventionNames":["Drug: Bromfenac Ophthalmic Solution B"]},{"label":"Placebo Comparator","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo Comparator"]}],"interventions":[{"name":"Bromfenac Ophthalmic Solution A","otherNames":[]},{"name":"Bromfenac Ophthalmic Solution B","otherNames":[]},{"name":"Placebo Comparator","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Be of either gender and any race 18 years or older\n\nExclusion Criteria:\n\n* Have a local or systemic disease that could interfere with the assessment of safety or efficacy or that is likely to result in early discontinuation from the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Mean Ocular Surface Disease Index (OSDI) Total Score","description":"The Ocular Surface Disease Index (OSDI) is a 12 item questionnaire. Each question about discomfort/limitations is scored from 0 to 4, with 0 being 'None of the Time' and 4 being 'All of the Time'. The minimum total score is 0 and the maximum total score is 48, with higher scores indicating worse outcomes.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35.0","spread":"22.23"},{"groupId":"OG001","value":"40.3","spread":"25.22"},{"groupId":"OG002","value":"36.9","spread":"23.24"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":141},"commonTop":["Dry eye"]}}}